Featured Research

from universities, journals, and other organizations

Using gene therapy to prevent heart failure

Date:
November 16, 2010
Source:
Nova Southeastern University
Summary:
A researcher has discovered how to use gene therapy to block a protein that can contribute to heart failure.

A Nova Southeastern University (NSU) researcher has discovered how to use gene therapy to block a protein that can contribute to heart failure. The finding will appear in an upcoming issue of the Journal of the American College of Cardiology.

Anastasios Lymperopoulos, Ph.D., an NSU College of Pharmacy assistant professor of pharmacology, has discovered a novel method, using gene therapy, to block the actions of a gene-encoded protein known as beta-arrestin 1, which causes an increase of aldosterone production from the body's adrenal glands into the blood. Aldosterone is a hormone. It increases the reabsorption of sodium and water into the kidneys, causing high blood volume and blood pressure. It also has several direct damaging effects on the heart, such as fibrosis, hypertrophy, and inflammation.

An increase in blood volume causes high blood pressure. This in turn decreases the pumping action of the heart, and is one of the causes of heart failure.

By finding a way to block beta-arrestin 1 through this gene therapy approach, Prof. Lymperopoulos hopes it will lead to the reduction of the severity of heart failure. He is now testing new and existing heart failure medications such as Cozaar, Diovan and Atacand, to see how effective they are at blocking this damaging effect of beta-arrestin on the heart.

Lymperopoulos receives funding from the American Heart Association through a Scientist Development Grant for his research at NSU.


Story Source:

The above story is based on materials provided by Nova Southeastern University. Note: Materials may be edited for content and length.


Cite This Page:

Nova Southeastern University. "Using gene therapy to prevent heart failure." ScienceDaily. ScienceDaily, 16 November 2010. <www.sciencedaily.com/releases/2010/11/101116122903.htm>.
Nova Southeastern University. (2010, November 16). Using gene therapy to prevent heart failure. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/11/101116122903.htm
Nova Southeastern University. "Using gene therapy to prevent heart failure." ScienceDaily. www.sciencedaily.com/releases/2010/11/101116122903.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins